Next-Generation Alzheimer's Management:
Early Identification, New Therapeutic Advances, and Patient-Centered Care
0.50 AMA PRA Credits
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions
Program Overview
Alzheimer’s disease (AD) is a growing public health crisis, with millions affected and cases rising. Early diagnosis is essential, especially with the advent of disease-modifying treatments (DMTs). However, many healthcare providers—particularly in rural and underserved areas—struggle to recognize early signs and use biomarkers effectively, leading to delayed diagnoses, missed interventions, and higher healthcare costs.
This program addresses these challenges through an adaptive learning platform that personalizes education and equips providers with essential tools. The interactive experience ensures accurate, timely diagnosis and intervention, enhancing patient outcomes across diverse care settings.
This program addresses these challenges through an adaptive learning platform that personalizes education and equips providers with essential tools. The interactive experience ensures accurate, timely diagnosis and intervention, enhancing patient outcomes across diverse care settings.
Target Audience
This activity has been designed to meet the educational needs primary care clinicians, neurologists, geriatricians, and other HCPs who collaborates to recognize and manage Alzheimer's disease.
Supporter Acknowledgement
This educational activity is supported by an independent educational grant from Eisai Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- EXPLAIN the adverse impacts of delayed AD diagnosis on patients and their families.
- IMPLEMENT the use of biomarkers to aid in the early AD diagnosis.
- EVALUATE the challenges linked to the shortage of AD specialists.
- ASSESS the implications for accessing specialized Alzheimer's care through novel diagnostic and treatment models of care.
- IMPLEMENT team-based caregiver support initiatives.
- STATE how telemedicine can improve the diagnostic and treatment windows, bolster caregiver support, and enrich the healthcare landscape in rural communities.
- SUMMARIZE the mechanisms of action, efficacy, and safety information for disease-modifying therapies that are currently approved or being developed for AD.
Accredited Provider
This activity is jointly provided by Global Education Group and Iridium Continuing Education.


AMA PRA Category 1 Credit™
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium CE. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Designation Statement
Global Education Group designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty, Staff, and Planners’ Disclosures
Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures of Relevant Financial Relationship(s)
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
James E. Galvin,
MD, MPH
MD, MPH
Alexandria and Bernard Schoninger Endowed Chair in Memory Disorders
Professor of Neurology, Psychiatry and Behavioral Sciences
Chief, Division of Cognitive Neurology
Director, Comprehensive Center for Brain Health
Director and Principal Investigator, Lewy Body Dementia Research Center of Excellence
Director and Principal Investigator, Native Alzheimer’s Disease Resource Center for Minority Aging Research
Department of Neurology
University of Miami Miller School of Medicine
Professor of Neurology, Psychiatry and Behavioral Sciences
Chief, Division of Cognitive Neurology
Director, Comprehensive Center for Brain Health
Director and Principal Investigator, Lewy Body Dementia Research Center of Excellence
Director and Principal Investigator, Native Alzheimer’s Disease Resource Center for Minority Aging Research
Department of Neurology
University of Miami Miller School of Medicine
Consulting Fee (e.g., Advisory Board):
Biogen, Cognivue, Eisai, Eli Lilly, GE Healthcare, Genentech, Roche
Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):
Cognivue
Instructions to Receive Credit
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures Complete the pretest
- View the broadcast
- Complete the posttest with a score of 70% or higher
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com
System Requirements

Copyright © 2024


Stay Informed
To receive updates as soon as the new dates are confirmed, please share your email.
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
Thank you!